

Comment on: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand *et al*

I read with great interest the paper by Eric Morand and colleagues¹ reporting on the utility of the Lupus Low Disease Activity State attainment using a useful form of discrimination in the phase IIb MUSE Anifrolumab trial published recently in the journal. The manuscript makes a useful contribution to this important debate but does contain one important error which should be corrected.

In the discussion, the authors state 'The assumption that gastrointestinal activity, which is not measured in the SLEDAI-2K or BILAG...' is simply incorrect. British Isles Lupus Assessment Group (BILAG)-2004² has a whole section dedicated to capturing gastrointestinal disease. It is one of several facets of lupus activity captured in BILAG but not captured in SLEDAI-2K (others include haemolytic anaemia and ophthalmic disease).

David Isenberg

Correspondence to Professor David Isenberg, Centre for Rheumatology Research, Division of Medicine, UCL, London WC1E 6BT, UK; d.isenberg@ucl.ac.uk

Handling editor Josef Smolen

Contributors DI is the sole author of this letter.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Isenberg D. *Ann Rheum Dis* 2019;**78**:e121.

Received 20 September 2018

Accepted 22 September 2018

Published Online First 29 October 2018



► <https://doi.org/10.1136/annrheumdis-2018-214487>

Ann Rheum Dis 2019;**78**:e121. doi:10.1136/annrheumdis-2018-214468

REFERENCES

- 1 Morand EF, Trasieva T, Berglind A, *et al*. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: *post-hoc* analysis of the Phase IIb MUSE trial of anifrolumab. *Ann Rheum Dis* 2018;**77**:706–13.
- 2 Yee CS, Farewell V, Isenberg DA, *et al*. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. *Arthritis Rheum* 2006;**54**:3300–5.
- 3 Morand EF, Trasieva T, Berglind A, *et al*. Regarding gastrointestinal activity in SLE, SLEDAI, BILAG, and PGA. *Ann Rheum Dis* 2019;**78**:e122–e122.